Related Experiment Videos
Experience with lamivudine against hepatitis B virus
1Department of Gastroenterology and Hepatology, Medizinische Hochschule Hannover, Germany.
Intervirology
|January 1, 1997
Summary
Lamivudine offers a promising treatment for chronic hepatitis B virus (HBV) infection, showing high effectiveness. However, viral resistance development remains a significant challenge for long-term therapy.
Area of Science:
- Hepatology
- Virology
- Pharmacology
Background:
- Chronic hepatitis B virus (HBV) infection has limited effective treatments.
- Nucleoside analogues have shown minimal success against HBV previously.
Purpose of the Study:
- To review lamivudine's efficacy and molecular action in treating chronic HBV.
- To explore lamivudine's use in specific patient populations and combination therapies.
- To address the challenge of drug resistance in lamivudine therapy.
Main Methods:
- Review of clinical studies on lamivudine for various HBV indications.
- Analysis of nucleoside metabolism and lamivudine's molecular mechanism.
- Comparison of resistance development with HIV infection.
Main Results:
- Lamivudine demonstrates high initial effectiveness against chronic HBV.
- Resistance mutations in the viral polymerase emerge as a significant clinical issue.
- Lamivudine shows potential in specific contexts like immunosuppression and post-transplant prophylaxis.
Conclusions:
- Lamivudine is a valuable therapeutic option for chronic HBV infection.
- Viral resistance is a key limitation requiring further research and management strategies.
- Combination therapies and understanding cross-resistance are crucial for future treatment perspectives.